Navigation Links
Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd
Date:7/14/2008

Company's DSU Products offer biologically safer water through point-of-use

ultrafiltration

NEW YORK, July 14 /PRNewswire-FirstCall/ -- Nephros, Inc. (Amex: NEP), a medical device company, announced today that it will be exhibiting its Dual Stage Ultrafilter products at the American Society for Healthcare Engineering (ASHE) Conference and Technical Exhibition in National Harbor, Maryland, July 20th-23rd, 2008. Building on the success of the Nephros online hemodiafiltration technology, the Nephros Dual Stage Ultrafilter (DSU) delivers water free of bacteria, viruses, fungi, and other biologically hazardous elements. The Company believes the DSU can be an important addition to the hospital's arsenal in addressing water-borne hospital acquired infection (HAI) risks, and therefore help to reduce infection-related hospital costs and liability associated with prolonged hospital stays, additional care requirements, and patient mortality.

HAIs of all types are a significant problem in the U.S. According to the Centers for Disease Control and Prevention (CDC), there are over 2 million HAIs annually in the U.S., resulting in an estimated $30.5 billion in additional healthcare costs and over 100,000 in-hospital deaths. The federal Medicare program recently announced that, beginning in October 2008, it will no longer pay extra costs associated with certain types of HAIs. A variety of pathogens survives and even thrives in hospital plumbing systems despite chemical and heat-based treatments designed to eradicate them.

"Hospitals and related healthcare settings recognize that water-borne pathogens represent a substantial risk, and are taking measures to protect their patient populations accordingly. We be
'/>"/>

SOURCE Nephros, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Nephros Appoints Gerald J. Kochanski as Chief Financial Officer
2. BioSpace Career Fair in Bethesda, Maryland Draws Hundreds of Industry Professionals
3. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
4. University of Maryland, Baltimore BioPark Signs Gliknik Inc. as First Tenant in Its BioInnovation Center in Building Two
5. Maryland Science Center Unveils Anatomical Exhibition, Body Worlds 2, on Saturday, February 2
6. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
7. Maryland Stem Cell Research Commission Recommends 62 Projects for Funding
8. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
9. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
10. Avicena Group to Present at Noble Financial Conference
11. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
Other Biology Technology:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase 2Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase 3Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase 4Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase 5Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase 6Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase 7Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase 8Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase 9Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase 10Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase 11Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase 12Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase 13Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 2Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 3Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 4Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 5Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 6Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 7Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 8Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 9Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results 10